Ultimately, the significant increase in ROS, and the reduction in LSCs driven by CKS1i, indicates a clear pathway to target CKS1Bhigh LSCs in vivo, regardless of bulk CKS1B status in AML. This evidence concerns the gene CKS1B and acute myeloid leukemia.